Hikma Pharma’s Study on Generic Imatinib: A Potential Game Changer in Leukemia Treatment

Hikma Pharma ((HKMPY)) announced an update on their ongoing clinical study.

Hikma Pharmaceuticals is leading a study titled ‘Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia.’ The study aims to evaluate the effectiveness and safety of the generic drug Carcemia® against the established Glivec® in treating chronic myeloid leukemia, a significant step in providing cost-effective treatment options.

The study tests two drugs: Carcemia®, a generic version of Imatinib, and Glivec®, the original branded version. Both are intended to manage chronic myeloid leukemia effectively.

This observational study follows a cohort model with a prospective time perspective, meaning it observes outcomes in groups of patients over time without intervention by the researchers. The primary purpose is to assess real-world efficacy and safety.

The study began on March 3, 2022, and is currently recruiting participants. The latest update was submitted on March 23, 2025, indicating ongoing data collection and analysis.

For investors, the study’s progress could impact Hikma’s stock performance, especially if Carcemia® proves as effective as Glivec®, potentially capturing market share from more expensive branded treatments. This could also influence competitor strategies in the generic drug market.

The study is ongoing, with further details available on the ClinicalTrials portal.